Results 171 to 180 of about 7,686 (201)

Evolocumab in Hyperlipidemia

New England Journal of Medicine, 2014
Dirk J, Blom, Scott M, Wasserman, Evan A, Stein   +2 more
openaire   +4 more sources

Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials

European Heart Journal, 2022
Paul Guedeney, Gennaro Giustino, Sabato Sorrentino   +2 more
exaly  

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

New England Journal of Medicine, 2017
Marc S Sabatine, Robert P Giugliano, Anthony C Keech   +2 more
exaly  

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

Lancet, The, 2015
Frederick J Raal, Dirk J Blom, G Kees Hovingh   +2 more
exaly  

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Lancet Diabetes and Endocrinology,the, 2017
Marc S Sabatine, Lawrence A Leiter, Robert P Giugliano   +2 more
exaly  

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease

Circulation, 2018
Marc P Bonaca, Robert P Giugliano, Anthony C Keech   +2 more
exaly  

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke, 2020
Robert P Giugliano, Jeffrey L. Saver, Anthony C Keech   +2 more
exaly  

Alirocumab/evolocumab

Reactions Weekly, 2021
openaire   +1 more source

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Lancet Diabetes and Endocrinology,the, 2017
Frederick J Raal, G Kees Hovingh, Dirk J Blom   +2 more
exaly  

Cost-effectiveness of Evolocumab

Revista Española de Cardiología (English Edition), 2018
Carlos, Escobar, Vivencio, Barrios
openaire   +2 more sources